Novalon: 'Chemical genomics'

It has become a truism that genomics is providing thousands of new drug targets, creating bottlenecks in the lead discovery process at the level of functional genomics and compound screening. Novalon Pharmaceutical Corp. is addressing both problems with technology it believes will overcome the shortcomings of other screening methods.

"The real need in the post-genomics era is for a tool kit that lets you put a screen in place that can identify lead compounds," said Chairman,

Read the full 751 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE